FCR achieves long-term durable remissions in patients with <i>IGHV</i>-mutated CLL.

Chai-Adisaksopha, Chatree; Brown, Jennifer R

FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.

Chai-Adisaksopha, Chatree; Brown, Jennifer R.

Affiliation

Chai-Adisaksopha C; Department of Medicine and.
Brown JR; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; and.

Blood ; 130(21): 2278-2282, 2017 11 23.

Article in En | MEDLINE | ID: mdl-29025740

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Immunoglobulin Heavy Chains/genetics; Immunoglobulin Variable Region/genetics; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell/genetics; Mutation/genetics; Remission Induction; Cyclophosphamide/therapeutic use; Disease-Free Survival; Female; Humans; Immunotherapy; Middle Aged; Rituximab/therapeutic use; Time Factors; Vidarabine/analogs & derivatives; Vidarabine/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Remission Induction / Immunoglobulin Variable Region / Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Immunoglobulin Heavy Chains / Mutation Type of study: Clinical_trials / Prognostic_studies / Systematic_reviews Limits: Female / Humans / Middle aged Language: En Journal: Blood Year: 2017 Type: Article

Fulltext

XML

PubMed Links

Search on Google